DAX24.132 +0,7%Est505.679 +0,3%MSCI World4.343 -0,1%Top 10 Crypto14,20 -4,7%Nas23.835 +0,5%Bitcoin92.996 +0,5%Euro1,1514 -0,1%Öl64,73 -0,2%Gold3.998 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Amazon 906866 BYD A0M4W9 TKMS thyssenkrupp Marine Systems TKMS00 Deutsche Telekom 555750 Lufthansa 823212 DroneShield A2DMAA Siemens Energy ENER6Y Palantir A2QA4J Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73 Novo Nordisk A3EU6F Humanoid Global A41B76 BioNTech (ADRs) A2PSR2
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Über 24.000 Punkten: DAX letztlich höher -- US-Börsen schließen uneins -- Palantir steigert Umsatz und Gewinn -- OpenAI, Amazon, ON Semiconductor, Berkshire Hathaway im Fokus
Top News
Bitcoin, Ether & Co: In diesen zehn Ländern zahlt man wenig oder gar keine Steuern auf Kryptowährungen Bitcoin, Ether & Co: In diesen zehn Ländern zahlt man wenig oder gar keine Steuern auf Kryptowährungen
Nebius-Aktie stellt NVIDIA und Palantir in den Schatten: Was steckt hinter dem KI-Neuling? Nebius-Aktie stellt NVIDIA und Palantir in den Schatten: Was steckt hinter dem KI-Neuling?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Roche Aktie

Kaufen
Verkaufen
279,27 EUR -0,61 EUR -0,22 %
BMN
259,50 CHF +0,60 CHF +0,23 %
SWX
Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.221,35 Mrd. EUR

KGV24,60Div. Rendite3,80%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN855167

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCH0012032048

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRHHVF

Roche Aktien News

DatumMeistgelesen
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
GlobeNewswireRoche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
PR NewswireRoche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
GlobeNewswireMajority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
GlobeNewswireFDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
GlobeNewswireRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
PR NewswireSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public
PR NewswireSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public
GlobeNewswirePositive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
GlobeNewswireRoche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
GlobeNewswireWHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
GlobeNewswirePositive phase III results show Xofluza significantly reduces the transmission of influenza viruses
GlobeNewswireFDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
GlobeNewswireFDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
GlobeNewswireRoche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
PR NewswireRoche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
PR NewswireRoche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
GlobeNewswireRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
GlobeNewswireRoche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
GlobeNewswireRoche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
GlobeNewswireEuropean Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
GlobeNewswireRoche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
GlobeNewswireNew data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
GlobeNewswireRoche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
PR NewswireRemix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
GlobeNewswireRoche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
GlobeNewswireRoche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
GlobeNewswireFDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
GlobeNewswireRoche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
GlobeNewswireCHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
GlobeNewswireRoche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
GlobeNewswireRoche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
GlobeNewswireRoche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
GlobeNewswireRoche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
PR NewswireRoche receives FDA clearance on its digital pathology solution for diagnostic use
GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
GlobeNewswireRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.